<p>What’s changing in ovarian cancer treatment - and who has access to it?</p><p>In this episode, we dive into the biggest innovations transforming ovarian cancer care - from “smart” targeted treatments like PARP inhibitors and antibody-drug conjugates (ADCs), to advances in surgery, immunotherapy, and biomarker testing that help match the right patient to the right treatment. </p><p>But do women around the world have equitable access to these breakthroughs? We explore the real-world barriers patients face - from awareness gaps to issues with access and cost - as well as the significant socioeconomic impact of the disease.</p><p>Host Hannah Vaughan Jones is joined by Isabelle Raq-Coquard, Oncologist, Centre Léon Bérard, Professor of Medecine, Université Claude Bernard Lyon 1 and Co-Chair of the Lancet Commission on Ovarian Cancer. Frances Reid, who led the World Ovarian Cancer Coalition’s groundbreaking <em>Every Woman</em> studies returns to the podcast with her insights.</p><p>The conversation also looks ahead to more personalised care, the growing focus on prevention (including opportunistic salpingectomy - we explain what this is!), and the real hope that earlier detection and improved treatments could transform outcomes for patients in the years ahead.</p><p><br></p><p>Listen to the full episode to understand what’s changing - and what still needs to.</p><p><br></p><p>This episode is sponsored by AbbVie and Verastem.</p>